Apellis Pharmaceuticals (APLS) Surges 5.8%: Is This an Indication of Further Gains?

Apellis Pharmaceuticals, Inc. (APLS) shares ended the last trading session 5.8% higher at $23.07. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 13.6% loss over the past four weeks.The sudden price rise can be attributed to growing investor optimism related to the company’s marketed product, Empaveli (pegcetacoplan), which is approved for treating paroxysmal nocturnal hemoglobinuria in the United States. The drug ...